Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss
The FDA recently approved the cellular rejuvenation therapy ER-100 for human clinical trials. While vision is the first target, it could have applications for a variety of age-related disease.
本文内容来源于互联网，版权归原作者所有
查看原文